



## SUVEN LIFE SCIENCES LTD

Off: SDE Serene Chambers, 6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034


STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2020.

Rs. In Lakhs

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 Months period ended		For the year ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
		UN AUDITED	UN AUDITED	Refer No 8	UN AUDITED	Refer No 8	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	<b>Income</b>						
	Revenue from operations	151.30	897.96	277.26	1,192.12	575.47	1,441.47
	Other Income	162.41	227.72	585.53	643.06	1,103.92	1,403.63
	<b>Total income</b>	<b>313.71</b>	<b>1,125.68</b>	<b>862.79</b>	<b>1,835.18</b>	<b>1,679.39</b>	<b>2,845.10</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	379.91	486.15	242.29	1,206.73	1,111.35	1,459.51
	d) Finance costs	16.70	25.32	9.81	63.95	30.82	54.03
	e) Depreciation and amortisation expense	114.11	107.46	85.50	328.06	311.63	416.87
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	730.42	701.93	638.55	1,927.08	2,018.11	2,594.44
	h) Other Expenses	77.96	94.25	332.57	258.64	764.61	913.86
	<b>Total expenses</b>	<b>1,319.10</b>	<b>1,415.11</b>	<b>1,308.72</b>	<b>3,784.46</b>	<b>4,236.52</b>	<b>5,438.71</b>
3	Profit before exceptional items & Tax (1-2)	(1,005.39)	(289.43)	(445.93)	(1,949.28)	(2,557.13)	(2,593.61)
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(1,005.39)	(289.43)	(445.93)	(1,949.28)	(2,557.13)	(2,593.61)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	197.18
	b) Deferred tax	(190.68)	(99.46)	4.22	(536.86)	(1,438.16)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(814.71)	(189.97)	(450.15)	(1,412.42)	(1,118.97)	(1,375.32)
8	<b>Other Comprehensive Income</b>						
8.a	(i) Items that will not be reclassified to profit or loss	(11.36)	(11.35)	(14.41)	(34.06)	(16.53)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.97	3.96	5.04	11.90	5.78	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(7.39)</b>	<b>(7.39)</b>	<b>(9.37)</b>	<b>(22.16)</b>	<b>(10.75)</b>	<b>(29.54)</b>
9	Total Comprehensive Income for the period (7+8)	(822.10)	(197.36)	(459.52)	(1,434.58)	(1,129.72)	(1,404.86)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	37,494.53
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.64)	(0.15)	(0.35)	(1.11)	(0.88)	(1.08)
	b) Diluted	(0.64)	(0.15)	(0.35)	(1.11)	(0.88)	(1.08)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 9 Months period ended		For the year ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
		UN AUDITED	UN AUDITED	Refer No 8	UN AUDITED	Refer No 8	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	151.30	897.96	277.26	1,192.12	575.47	1,441.47
	Other Income	162.41	227.72	585.53	643.06	1,103.92	1,403.63
	Total income	313.71	1,125.68	862.79	1,835.18	1,679.39	2,845.10
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	450.14	571.74	332.26	1,435.70	1,307.70	1,740.91
	d) Finance costs	17.52	26.08	10.21	66.03	31.91	55.14
	e) Depreciation and amortisation expense	114.11	107.46	85.50	328.06	311.63	416.87
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	2,273.74	1,979.74	2,370.78	5,307.15	7,538.87	10,322.64
	h) Other Expenses	88.17	105.78	341.18	288.98	793.41	949.62
	Total expenses	2,943.68	2,790.80	3,139.93	7,425.92	9,983.52	13,485.18
3	Profit before exceptional items , Tax (1-2)	(2,629.97)	(1,665.12)	(2,277.14)	(5,590.74)	(8,304.13)	(10,640.08)
4	Exceptional Items- (Ref Note:7)	-	-	-	-	-	-
5	Profit before Tax (3-4)	(2,629.97)	(1,665.12)	(2,277.14)	(5,590.74)	(8,304.13)	(10,640.08)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	197.18
	b) Deferred tax	(190.68)	(99.46)	4.22	(536.86)	(1,438.16)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(2,439.29)	(1,565.66)	(2,281.36)	(5,053.88)	(6,865.97)	(9,421.79)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.36)	(11.35)	(14.41)	(34.06)	(16.52)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.97	3.96	5.03	11.90	5.77	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(7.39)	(7.39)	(9.38)	(22.16)	(10.75)	(29.54)
9	Total Comprehensive Income for the period ( 7+ 8)	(2,446.68)	(1,573.05)	(2,290.74)	(5,076.04)	(6,876.72)	(9,451.33)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	-	-	13,062.02
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.92)	(1.23)	(1.79)	(3.97)	(5.39)	(7.40)
	b) Diluted	(1.92)	(1.23)	(1.79)	(3.97)	(5.39)	(7.40)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	



**NOTES:-**

- 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 28 ,2021 . The above results have been subjected to limited review by the statutory auditors of the company
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary , Suven Neurosciences , Inc
- 4).The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.
- 5) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant , certain fixed assets and other contents in buildings was damaged. During the period ended December 31, 2020, the company has written off net book value of assets aggregating Rs 91.56 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .
- 6) The COVID-19 did not have impact on the business and research operations, which includes our subsidiary, Suven Neurosciences, Inc.
- 7) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad  
Date : January 28 , 2021



For SUVEN LIFE SCIENCES LTD

*Venkata Jasti*

**VENKAT JASTI**  
Chairman & CEO  
DIN: 00278028